Healthy ParticipantsPhase 1NCT07919314
A Study to Evaluate the Effects of Therapeutic and Supratherapeutic Doses of KRP-S124 Compared to Placebo With Moxifloxacin on QTc Interval in Healthy Participants
A Phase 1 study testing KRP-S124 Low Dose, Moxifloxacin and KRP-S124 Medium Dose in people with Healthy Participants, run by Kyorin Pharmaceutical Co.,Ltd at 1 site in Canada.
Trial summary
This study is being done to see how KRP-S124 affects the electrical activity of the heart (known as the QTc interval [QT interval corrected for heart rate]) in healthy volunteers. This helps researchers check the heart safety of the study drug. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Participants
- What is being tested?
- KRP-S124 Low Dose, Moxifloxacin and KRP-S124 Medium Dose
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteCanada
- Study dates
- 14 Oct 2026to 12 Feb 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Male or non-childbearing potential female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), greater than or equal to (>=) 18 and less than or equal to (<=) 55 years of age, with body mass index (BMI) greater than (>) 18.5 and less than (<) 30.0 kilograms per square meter (kg/m^2) and body weight >=50.0 kilograms (kg) for males and >=45.0 kg for females.
- Female participants of non-childbearing potential should not donate ova for 90 days after the last dose.
- Male participants (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the first dose and for 90 days after the last dose.
- Male participants must be willing not to donate sperm for 90 days after the last dose.
- Able to understand the study procedures and provide signed informed consent to participate in the study.
Who cannot join
- Any clinically significant abnormal finding at physical examination at screening or Baseline (Day -1 of Period 1).
- Clinically significant abnormal laboratory test results or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody at screening.
- Any of the following laboratory parameters above the upper limit of normal (ULN) values at Screening or Baseline (Day -1 of Period 1): alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl-transpeptidase (GGT), direct bilirubin and total bilirubin. Only abnormal values between 1-1.5 * ULN may be repeated once for confirmation to below ULN.
- Known allergic reactions to KRP-S124 or other related drugs, or to any excipient in the formulation.
- Clinically significant vital signs abnormalities (systolic blood pressure lower than 90 or over 140 millimeters of mercury [mmHg], diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 beats per minute [bpm]) at screening or Baseline (Day -1 of Period 1).
- History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) within 1 month or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 3 months prior to screening.
Show all 10Show fewer
- History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 10 units for women or 15 units for men of alcohol per week (1 unit = 340 mL of beer 5 percent (%), 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
- Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to the first dosing (or 5 half-lives, whichever is longer), administration of a biological product in the context of a clinical research study within 90 days prior to the first dosing (or 5 half-lives, whichever is longer), or concomitant participation in an investigational study involving no drug or device administration.
- History of sustained and non-sustained cardiac arrhythmias (ECG demonstrated), family history of sudden cardiac death, and history of additional risk factors for Torsade-de-pointes, (e.g. [for example]: heart failure, hypokalemia, unexplained syncope, family history of Long QT Syndrome).
- Any reason which, in the opinion of the Investigator, would prevent the participant from participating in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Clinical Development Center Kyorin Pharmaceutical Co., Ltd. contact
About this study
Official title: A Randomized, Partially Double-Blind, Five-Period, Five-Treatment, Crossover Study to Assess the Effects of KRP-S124 on QTc Interval Using Therapeutic and Supratherapeutic Doses Compared to Placebo, With Moxifloxacin as a Positive Control, in Healthy Participants: A Thorough QTc Study
This study is being done to see how KRP-S124 affects the electrical activity of the heart (known as the QTc interval [QT interval corrected for heart rate]) in healthy volunteers. This helps researchers check the heart safety of the study drug.
- Conditions
- Healthy Participants
- Being tested
- KRP-S124 Low Dose, Placebo, Moxifloxacin, KRP-S124 Medium Dose, KRP-S124 High Dose
- Keywords
- Thorough QT Study, KRP-S124
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
KRP-S124 Low DoseDrug
Orally.
PlaceboOther
Orally.
MoxifloxacinDrug
Orally.
KRP-S124 Medium DoseDrug
Orally.
KRP-S124 High DoseDrug
Orally.
| Study group | Role | What they receive |
|---|---|---|
| Treatment T (Therapeutic Dose) | Experimental | Participants will receive a single oral dose of Therapeutic dose (T) (KRP-S124 [low dose]) and placebo matched to KRP-S124. Receives: Drug: KRP-S124 Low Dose; Other: Placebo |
| Treatment ST1 (Supratherapeutic Dose 1) | Experimental | Participants will receive a single oral dose of Supratherapeutic dose 1 (ST1) (KRP-S124 [medium dose]) and placebo matched to KRP-S124. Receives: Other: Placebo; Drug: KRP-S124 Medium Dose |
| Treatment ST2 (Supratherapeutic Dose 2) | Experimental | Participants will receive a single oral dose of Supratherapeutic dose 2 (ST2) (KRP-S124 [high dose]). Receives: Drug: KRP-S124 High Dose |
| Treatment P (Placebo) | Placebo comparator | Participants will receive a single oral dose of placebo matched to KRP-S124. Receives: Other: Placebo |
| Treatment M (Moxifloxacin) | Active comparator | Participants will receive a single oral dose of moxifloxacin (M). Receives: Drug: Moxifloxacin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Placebo-corrected Change From Baseline in Fridericia's Corrected QT interval (delta delta [ΔΔ]QTcF) for KRP-S124
Placebo-corrected change from baseline QTcF will be reported using a linear mixed-effects model analysis.
Measured: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Secondary outcomes (19)
Placebo-corrected Change From Baseline in Heart Rate (ΔΔHR) for KRP-S124
Placebo-corrected change from baseline HR will be reported using a linear mixed-effects model analysis.
Measured: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Placebo-corrected Change From Baseline in PR interval (ΔΔPR) for KRP-S124
Placebo-corrected change from baseline PR interval will be reported using a linear mixed-effects model analysis.
Measured: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Placebo-corrected Change From Baseline in QRS interval (ΔΔQRS) for KRP-S124
Placebo-corrected change from baseline in QRS interval will be reported using a linear mixed-effects model analysis.
Measured: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Number of Participants With Categorical Outliers for QTcF, HR, PR and QRS
HR, PR, QRS, and QTc will be measured by continuous electrocardiogram (ECG) recordings. Number of participants with categorical outliers for QTcF, HR, PR and QRS will be reported.
Measured: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Number of Participants With Treatment-emergent Changes in ECG Morphology for KRP-S124
Measured: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC0-t) for KRP-S124 and Moxifloxacin
Measured: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for KRP-S124 and Moxifloxacin
Measured: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Percentage of AUC0-inf Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (Residual Area) for KRP-S124 and Moxifloxacin
Residual area will be calculated as [1 - (AUC0-t divided by AUC0-inf)] multiplied by 100.
Measured: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Maximum Observed Plasma Concentration (Cmax) for KRP-S124 and Moxifloxacin
Measured: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Time to Reach Maximum Observed Plasma Concentration (Tmax) for KRP-S124 and Moxifloxacin
Measured: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Terminal Elimination Half-life (T1/2 el) for KRP-S124 and Moxifloxacin
Measured: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Terminal Elimination Rate Constant (Kel) for KRP-S124 and Moxifloxacin
Measured: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Apparent Clearance (Cl/F) for KRP-S124 and Moxifloxacin
Measured: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Apparent Volume of Distribution (Vz/F) for KRP-S124 and Moxifloxacin
Measured: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Number of Participants With Adverse Events
Measured: Up to approximately 10 weeks
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Values
Measured: Up to approximately 10 weeks
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Measurements
Measured: Up to approximately 10 weeks
Number of Participants With Clinically Significant Changes From Baseline in 12-lead Safety ECG Measurements
Measured: Up to approximately 10 weeks
Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings
Measured: Up to approximately 10 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Nov 2026
- Study start14 Oct 2026
- Primary completion1 Feb 2027 (estimated)
- Study completion12 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy ParticipantsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Kyorin Pharmaceutical Co.,Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07919314
- Sponsor's protocol ID
- KRPS124-T101
- Status last verified
- Oct 2026
- First submitted
- 31 Oct 2026
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Partially Double-Blind, Five-Period, Five-Treatment, Crossover Study to Assess the Effects of KRP-S124 on QTc Interval Using Therapeutic and Supratherapeutic Doses Compared to Placebo, With Moxifloxacin as a Positive Control, in Healthy Participants: A Thorough QTc Study
- ClinicalTrials.gov ID
- NCT07919314
- Acronym / sponsor ID
- KRPS124-T101
- Conditions
- Healthy Participants
- Keywords
- Thorough QT Study, KRP-S124
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Kyorin Pharmaceutical Co.,LtdIndustry (pharma, biotech, devices)
- Study start
- 14 Oct 2026 (actual)
- Primary completion
- 1 Feb 2027 (estimated)
- Study completion
- 12 Feb 2027 (estimated)
- First posted
- 5 Nov 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is being done to see how KRP-S124 affects the electrical activity of the heart (known as the QTc interval [QT interval corrected for heart rate]) in healthy volunteers. This helps researchers check the heart safety of the study drug.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| Treatment T (Therapeutic Dose) | Experimental | Drug: KRP-S124 Low Dose, Other: PlaceboParticipants will receive a single oral dose of Therapeutic dose (T) (KRP-S124 [low dose]) and placebo matched to KRP-S124. |
| Treatment ST1 (Supratherapeutic Dose 1) | Experimental | Other: Placebo, Drug: KRP-S124 Medium DoseParticipants will receive a single oral dose of Supratherapeutic dose 1 (ST1) (KRP-S124 [medium dose]) and placebo matched to KRP-S124. |
| Treatment ST2 (Supratherapeutic Dose 2) | Experimental | Drug: KRP-S124 High DoseParticipants will receive a single oral dose of Supratherapeutic dose 2 (ST2) (KRP-S124 [high dose]). |
| Treatment P (Placebo) | Placebo comparator | Other: PlaceboParticipants will receive a single oral dose of placebo matched to KRP-S124. |
| Treatment M (Moxifloxacin) | Active comparator | Drug: MoxifloxacinParticipants will receive a single oral dose of moxifloxacin (M). |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Male or non-childbearing potential female, non-smoker (no use of tobacco or nicotine products within 3 months prior to screening), greater than or equal to (>=) 18 and less than or equal to (<=) 55 years of age, with body mass index (BMI) greater than (>) 18.5 and less than (<) 30.0 kilograms per square meter (kg/m^2) and body weight >=50.0 kilograms (kg) for males and >=45.0 kg for females.
- Female participants of non-childbearing potential should not donate ova for 90 days after the last dose.
- Male participants (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the first dose and for 90 days after the last dose.
- Male participants must be willing not to donate sperm for 90 days after the last dose.
- Able to understand the study procedures and provide signed informed consent to participate in the study.
Key exclusion criteria (10 listed)
- Any clinically significant abnormal finding at physical examination at screening or Baseline (Day -1 of Period 1).
- Clinically significant abnormal laboratory test results or positive serology test results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen and antibody at screening.
- Any of the following laboratory parameters above the upper limit of normal (ULN) values at Screening or Baseline (Day -1 of Period 1): alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma glutamyl-transpeptidase (GGT), direct bilirubin and total bilirubin. Only abnormal values between 1-1.5 * ULN may be repeated once for confirmation to below ULN.
- Known allergic reactions to KRP-S124 or other related drugs, or to any excipient in the formulation.
- Clinically significant vital signs abnormalities (systolic blood pressure lower than 90 or over 140 millimeters of mercury [mmHg], diastolic blood pressure lower than 50 or over 90 mmHg, or heart rate less than 50 or over 100 beats per minute [bpm]) at screening or Baseline (Day -1 of Period 1).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| KRP-S124 Low DoseOrally. | Drug | Treatment T (Therapeutic Dose) |
| PlaceboOrally. | Other | Treatment P (Placebo), Treatment ST1 (Supratherapeutic Dose 1), Treatment T (Therapeutic Dose) |
| MoxifloxacinOrally. | Drug | Treatment M (Moxifloxacin) |
| KRP-S124 Medium DoseOrally. | Drug | Treatment ST1 (Supratherapeutic Dose 1) |
| KRP-S124 High DoseOrally. | Drug | Treatment ST2 (Supratherapeutic Dose 2) |
Primary outcome
Placebo-corrected Change From Baseline in Fridericia's Corrected QT interval (delta delta [ΔΔ]QTcF) for KRP-S124
Time frame: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Placebo-corrected change from baseline QTcF will be reported using a linear mixed-effects model analysis.
19 secondary outcomes
Placebo-corrected Change From Baseline in Heart Rate (ΔΔHR) for KRP-S124
Time frame: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Placebo-corrected Change From Baseline in PR interval (ΔΔPR) for KRP-S124
Time frame: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Placebo-corrected Change From Baseline in QRS interval (ΔΔQRS) for KRP-S124
Time frame: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Number of Participants With Categorical Outliers for QTcF, HR, PR and QRS
Time frame: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Number of Participants With Treatment-emergent Changes in ECG Morphology for KRP-S124
Time frame: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero Until the Last Observed Concentration (AUC0-t) for KRP-S124 and Moxifloxacin
Time frame: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) for KRP-S124 and Moxifloxacin
Time frame: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Percentage of AUC0-inf Due to Extrapolation From the Time of the Last Observed Concentration to Infinity (Residual Area) for KRP-S124 and Moxifloxacin
Time frame: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Maximum Observed Plasma Concentration (Cmax) for KRP-S124 and Moxifloxacin
Time frame: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Time to Reach Maximum Observed Plasma Concentration (Tmax) for KRP-S124 and Moxifloxacin
Time frame: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Terminal Elimination Half-life (T1/2 el) for KRP-S124 and Moxifloxacin
Time frame: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Terminal Elimination Rate Constant (Kel) for KRP-S124 and Moxifloxacin
Time frame: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Apparent Clearance (Cl/F) for KRP-S124 and Moxifloxacin
Time frame: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Apparent Volume of Distribution (Vz/F) for KRP-S124 and Moxifloxacin
Time frame: Pre-dose up to 12 hours post-dose on Day 1 and 24 hours post-dose on Day 2
Number of Participants With Adverse Events
Time frame: Up to approximately 10 weeks
Number of Participants With Clinically Significant Changes From Baseline in Clinical Laboratory Values
Time frame: Up to approximately 10 weeks
Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Measurements
Time frame: Up to approximately 10 weeks
Number of Participants With Clinically Significant Changes From Baseline in 12-lead Safety ECG Measurements
Time frame: Up to approximately 10 weeks
Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Findings
Time frame: Up to approximately 10 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Participants
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
RecruitingPhase 1
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants
Healthy Female Participants
Not yet recruiting
REM Enhancement Sleep Technology for Well-being, Emotion, and Life Lift
Healthy Adult Participants
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Clinical Development Center Kyorin Pharmaceutical Co., Ltd. contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing KRP-S124 Low Dose, Moxifloxacin and KRP-S124 Medium Dose in people with Healthy Participants, run by Kyorin Pharmaceutical Co.,Ltd at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Development Center Kyorin Pharmaceutical Co., Ltd. (+81-3-6368-4834, ml-kyorin_clinicaltrials.gov@mb.kyorin-pharm.co.jp), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Placebo-corrected Change From Baseline in Fridericia's Corrected QT interval (delta delta [ΔΔ]QTcF) for KRP-S124 (time frame: Baseline (pre-dose at -1.5, -1, -0.5 hours) up to 24 hours post-dose). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.